ALFA Finder| Revenue growth | FY26 standalone revenue declined 12% YoY. |
|---|---|
| Margins | Q4FY26 EBITDA margin improved to 17% from 16% YoY. |
| Demand visibility | Targeting 15-20% API and 80% FDF in $15Bn cephalosporin market. |
| Management confidence | High; stating turnaround is complete and platform creation is beginning. |
Growth
FY26 Revenue down 12% YoY (₹811 Cr vs ₹922 Cr); Q4FY26 PAT up 7% YoY to ₹30 Cr.
Outlook
₹750 Cr capex for 7ACA project (FY27 commissioning); plans for 5-6 sterile US launches by 2030.
Risks
Heavy dependence on cephalosporin segment (90%); ongoing execution risks for large-scale capex projects in Jammu.
Earnings Call filed with NSE, NSE: ORCHPHARMA. Summary written with AI assistance from the document.
Orchid Pharma Ltd: key numbers
- Share price
- ₹877.00
- Market cap
- ₹5,252 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 605.9×Sector 43.8×
- Promoter holding
- 74.45%+4.61% QoQ
- FII holding
- 0.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Board Meeting Date
Orchid Pharma Ltd intimated that its board will meet on November 14, 2026 to consider Q2 and half-year unaudited results. The trading window stays closed until 48 hours after results declaration.
Orchid Pharma Partnership
Orchid Pharma entered a licensing and supply agreement with Laboratorio Libra for Exblifep across nine Latin American markets. The partnership is expected to represent a potential opportunity of about USD 80 million over 10 years.
Orchid Pharma Fund Raise of ₹600 Cr
Orchid Pharma's board approved an enabling resolution to raise funds of up to ₹600 Crore through equity or debt securities via various permissible modes.
- Value
- ₹600.0 Cr
Orchid Pharma Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Orchid Pharma Board Meeting Date
Orchid Pharma has scheduled a board meeting for October 20, 2026, to consider options for raising funds. The company will explore various suitable funding avenues.
Orchid Pharma Other Announcement
Orchid Pharma Ltd has filed its quarterly Shareholding Pattern, providing a routine update on promoter and public shareholding as mandated by SEBI regulations.